Den samlede responsrate (komplet + partiel remission) var 45% (XELOX plus bevacizumab versus 47% (XELIRI plus bevacizumab).
Overall response rate (complete response plus partial response) was 45% (XELOX plus bevacizumab) versus 47% (XELIRI plus bevacizumab).